TIF3 Antibody

What is TIF3 and why are antibodies against it important for research?

TIF3 (Translation Initiation Factor 3) is a protein that plays a crucial role in the initiation of protein translation. Research has identified TIF3 as a potential proto-oncogene, particularly in cadmium-induced cell transformation. The predicted protein encoded by TIF3 cDNA exhibits 99% similarity to human eukaryotic initiation factor 3 p36 protein and has a molecular weight of approximately 36,000 Da . Antibodies against TIF3 are critical research tools for studying its expression, localization, and function in normal and pathological conditions, particularly in cancer models where TIF3 overexpression has been associated with tumorigenesis.

What challenges exist in developing effective TIF3 antibodies?

Developing specific antibodies against TIF3 presents several challenges. Historically, the unavailability of TIF3 antibodies has hindered research, as noted in studies where "antibody for the TIF3 protein was not available, [making] it not possible to determine the antisense mRNA-induced inhibition of translation of the TIF3 gene" . Key challenges include:

• Protein conservation across species - The high similarity between mouse TIF3 and human eIF3 p36 (99%) makes it difficult to generate species-specific antibodies

• Potential cross-reactivity with related translation initiation factors

• Accessibility of epitopes - Some regions of TIF3 may be obscured when the protein is in complex with other translation factors

• Validation challenges - Without established positive controls, confirming antibody specificity becomes problematic

What alternative methods can researchers use to study TIF3 when antibodies are unavailable?

When TIF3-specific antibodies are unavailable, researchers can employ several alternative approaches:

• mRNA expression analysis: Using real-time quantitative PCR with SYBR green, as demonstrated in studies where "expression of TIF3 mRNA was determined by real-time quantitative PCR using the SYBR green PCR and RT-PCR reagents"

• Epitope tagging strategies: Expressing TIF3 with fusion tags (His, V5, FLAG) for detection using commercial tag antibodies

• Antisense RNA approaches: As used in studies where "expression of the antisense RNA against TIF3 mRNA resulted in significant reversal of oncogenic potential"

• Protein overexpression systems: Transfection with expression vectors containing TIF3 cDNA, which can be confirmed through functional assays rather than direct protein detection

• CRISPR/Cas9 gene editing: For knockout or knockdown studies to assess TIF3 function indirectly

What are the optimal protocols for validating a new TIF3 antibody?

Rigorous validation of TIF3 antibodies is essential before application in research. A comprehensive validation protocol should include:

Step 1: Specificity Testing

• Western blot analysis comparing TIF3-expressing and knockout/knockdown cells

• Testing on recombinant TIF3 protein alongside related family members

• Peptide competition assays to confirm epitope specificity

Step 2: Application-Specific Validation

• For immunohistochemistry: Test on known positive and negative tissue samples

• For flow cytometry: Compare with isotype controls and perform blocking experiments

• For immunoprecipitation: Confirm pulldown of known TIF3 interaction partners

Step 3: Cross-Reactivity Assessment

• Testing across relevant species (mouse, human) to determine cross-reactivity

• Evaluation in cells with varying TIF3 expression levels

Validation Data Example:

How can researchers optimize immunodetection of TIF3 in transformed cells?

Detecting TIF3 in transformed cells requires optimized protocols due to potential low expression levels or accessibility issues:

• Sample preparation optimization:

  • For cell lysates: Use RIPA buffer with protease inhibitors and phosphatase inhibitors

  • For tissue samples: Consider antigen retrieval methods for formalin-fixed samples

• Signal amplification strategies:

  • Employ tyramide signal amplification for immunohistochemistry

  • Use highly sensitive chemiluminescent substrates for Western blots

  • Consider proximity ligation assays for detecting TIF3 interactions

• Controls and normalization:

  • Include CdCl₂-transformed BALB/c-3T3 cells as positive controls, as these have demonstrated consistent TIF3 overexpression where "overexpression of the transcript was detected in 100% of the transformed cell lines (10 of 10) developed from individual transformed foci of BALB/c-3T3 cells exposed to CdCl₂"

  • Use β-actin normalization for quantitative assessments

• Subcellular fractionation:

  • Separate nuclear and cytoplasmic fractions to enhance detection sensitivity

  • Compare distribution patterns between transformed and non-transformed cells

How does TIF3 overexpression contribute to cellular transformation and tumorigenesis?

TIF3 overexpression has been directly linked to cellular transformation and tumorigenesis through several experimental approaches:

• Transfection studies: Research has demonstrated that "transfection of NIH3T3 cells with an expression vector containing TIF3 cDNA resulted in overexpression of the encoded protein, and this was associated with cell transformation, as evidenced by the appearance of transformed foci exhibiting anchorage-independent growth on soft agar and tumorigenic potential in nude mice" .

• Antisense inhibition: Complementary evidence comes from antisense RNA experiments where "expression of the antisense RNA against TIF3 mRNA resulted in significant reversal of oncogenic potential of the CdCl₂-transformed BALB/c-3T3 cells" .

• Molecular mechanisms: As a translation initiation factor, TIF3 overexpression likely enhances translation of specific mRNAs involved in cell proliferation, survival, and transformation. The precise molecular targets remain an active area of investigation.

• Cadmium-induced carcinogenesis: TIF3 has been identified as "a novel cadmium-responsive proto-oncogene" , suggesting it may be a key mediator in environmental carcinogenesis.

What methods can be used to correlate TIF3 expression with tumorigenic potential?

Researchers investigating the relationship between TIF3 expression and tumorigenesis can employ several analytical approaches:

• In vitro transformation assays:

  • Focus formation assays in NIH3T3 cells

  • Soft agar colony formation to assess anchorage-independent growth

  • Cell migration and invasion assays

• In vivo tumorigenicity testing:

  • Xenograft models in immunodeficient mice where "immune-deficient athymic nude mice were injected s.c. with control and transformed NIH3T3 cells (2 × 10⁶ cells/mouse) and observed for development of tumor"

  • Measurement of tumor growth rates, invasion, and metastatic potential

• Correlation analysis:

  • Quantitative assessment of TIF3 mRNA levels using real-time PCR

  • Ideally, protein quantification using validated antibodies

  • Statistical correlation with transformation phenotypes

TIF3 Expression-Tumorigenicity Correlation Data:

How can TIF3 antibodies be integrated into multi-parameter flow cytometry panels?

Integrating TIF3 antibodies into multi-parameter flow cytometry requires careful panel design and optimization:

• Antibody conjugation considerations:

  • Select fluorochromes with minimal spectral overlap

  • Consider brightness of fluorochromes based on expected TIF3 expression levels

  • Validate antibody performance post-conjugation

• Panel design strategy:

  • Include markers for relevant cell populations (e.g., CD45, CD8, CD4 as used in checkpoint inhibitor studies)

  • Add markers for cell viability (e.g., "LIVE/DEAD™ Fixable Blue Dead Cell Stain Kit")

  • Consider including other checkpoint molecules like PD-1, TIM-3, and TIGIT for comprehensive analysis

• Intracellular staining protocol:

  • Fix cells with 2% paraformaldehyde

  • Permeabilize using commercial buffers (e.g., "BD Perm/Wash™ Buffer")

  • Include appropriate blocking steps to reduce non-specific binding

• Controls and analysis:

  • Use fluorescence minus one (FMO) controls

  • Include compensation controls for each fluorochrome

  • Consider using dimensionality reduction techniques (tSNE, UMAP) for complex datasets

What experimental approaches can determine if TIF3 antibodies have functional blocking properties?

Assessing the functional blocking properties of TIF3 antibodies requires specialized assays:

• In vitro translation inhibition assays:

  • Cell-free translation systems supplemented with TIF3 protein

  • Measurement of translation efficiency with and without antibody

  • Quantification of protein synthesis using reporter systems

• Cell-based functional assays:

  • Assessment of antibody effects on cell transformation phenotypes

  • Comparison with known effects of TIF3 antisense RNA, which has been shown to cause "significant reversal of oncogenic potential"

  • Dose-response studies to determine effective concentrations

• Protein-protein interaction disruption assays:

  • Co-immunoprecipitation studies with TIF3 binding partners

  • Assessment of whether antibody binding disrupts key protein interactions

  • Surface plasmon resonance or similar techniques to measure binding kinetics

• Epitope mapping:

  • Determination of antibody binding sites relative to functional domains

  • Prediction of functional effects based on structural knowledge

  • Comparison of multiple antibodies targeting different epitopes

How might TIF3 antibodies contribute to understanding checkpoint molecule interactions in cancer immunotherapy?

TIF3 research may intersect with cancer immunotherapy, particularly in understanding translation regulation of checkpoint molecules:

• Translational regulation of checkpoint molecules:

  • TIF3 may potentially regulate translation of checkpoint molecules like PD-1, TIM-3, and TIGIT

  • Investigation of whether "PD1 blockade was suboptimally therapeutic alone" and "the effect of TIM3 and TIGIT was upregulated on T cells in response to PD1 blockade" involves translational control

• Combined therapeutic approaches:

  • Potential for targeting translation initiation factors alongside checkpoint inhibition

  • Investigation of whether TIF3 inhibition could enhance effects of checkpoint blockade therapy

• Biomarker development:

  • TIF3 expression as a potential predictive biomarker for response to immunotherapy

  • Correlation studies between TIF3 levels and checkpoint molecule expression

What are the methodological considerations for developing phospho-specific TIF3 antibodies?

Developing phospho-specific TIF3 antibodies presents unique challenges that researchers should consider:

• Phosphorylation site identification:

  • Mass spectrometry analysis to identify physiologically relevant phosphorylation sites

  • Bioinformatic prediction of kinase target sites

  • Conservation analysis across species

• Immunogen design strategy:

  • Synthetic phosphopeptides corresponding to target sites

  • Carrier protein conjugation considerations

  • Phosphorylation stability during immunization

• Validation requirements:

  • Comparison of antibody reactivity with phosphorylated vs. dephosphorylated protein

  • Lambda phosphatase treatment controls

  • Mutational analysis of phosphorylation sites

• Application-specific considerations:

  • Buffer composition to preserve phosphorylation status

  • Phosphatase inhibitor requirements

  • Fixation methods that maintain phosphoepitopes

Phosphorylation Site Analysis Table: